




RealRate

# PHARMACEUTICAL 2021

Larimar Therapeutics Inc.  
Rank 198 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2021

## Larimar Therapeutics Inc. Rank 198 of 409

The relative strengths and weaknesses of Larimar Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 185% points. The greatest weakness of Larimar Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -123%, being 231% points above the market average of -355%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 97,952            |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 8,992             |
| Liabilities, Non-Current                    | 6,002             |
| Other Assets                                | 5,694             |
| Other Compr. Net Income                     | 2.0               |
| Other Expenses                              | 0                 |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 322               |
| Property and Equipment                      | 1,040             |
| Research and Development                    | 31,407            |
| Revenues                                    | 0                 |
| Selling, General and Administrative Expense | 11,397            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 104,686           |
| Liabilities              | 14,994            |
| Expenses                 | 42,804            |
| Stockholders Equity      | 89,692            |
| Net Income               | -42,482           |
| Comprehensive Net Income | -42,481           |
| Economic Capital Ratio   | -123%             |

